Neurizon Extends R&D Facility, Draws $12 Million Ahead Of ALS Trial Results
NUZ: $0.058 +1.75% · MC: $48M
Neurizon Therapeutics has extended its non-dilutive R&D financing facility to cover FY2027 and drawn approximately $3.7 million, bringing total advances to approximately $12 million before receiving the related tax rebates. Separately, the first participant in its HEALEY ALS trial’s Regimen I has entered the treatment extension after completing the randomised phase; topline results remain anticipated in late Q2 2027.

Comments